Xilio Therapeutics Amends Shelf Registration, Updates ATM Program to $14.5M with $4.6M Already Sold
XLO sits 29% above its 52-week low of $6.465.
Summary
Xilio Therapeutics updated its universal shelf registration, reducing its At-The-Market (ATM) program to $14.5 million and disclosing $4.6 million in prior sales, indicating continued dilutive capital raising for general corporate purposes.
Key Events · Financing and Capital Events · XLO
-
Amended Universal Shelf Registration
Xilio Therapeutics filed an S-3/A for a universal shelf registration, allowing it to offer up to $250 million in various securities. This amends the S-3 filed on May 12, 2026.
-
Updated At-The-Market (ATM) Program
The ATM program capacity has been updated to $14.5 million, a reduction from the $17.22 million previously registered on May 12, 2026.
-
Prior ATM Sales Disclosed
The company disclosed that $4,596,248 of common stock has already been sold under a prior ATM program, leaving approximately $9.9 million available under the current $14.5 million ATM.
-
Potential Dilution for New Investors
The filing highlights immediate and substantial dilution of $4.21 per share for new investors if the full $14.5 million ATM is sold at the assumed price of $8.35 per share.
Analysis · XLO · Life Sciences
Xilio Therapeutics filed an amendment to its universal shelf registration, updating its At-The-Market (ATM) offering program. The total ATM capacity is now set at $14.5 million, a reduction from the $17.22 million previously registered on May 12, 2026. The company also disclosed that $4,596,248 has already been sold under a prior ATM program, leaving approximately $9.9 million available under the current ATM. This ongoing capital raise is a significant dilutive event for the company, as explicitly noted by the immediate and substantial dilution of $4.21 per share for new investors if the full $14.5 million is sold. For a life sciences company with a market capitalization of approximately $50 million, securing capital is crucial for operations and extending its cash runway, which was previously reported to extend into early 2028.
At the time of this filing, XLO was trading at $8.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.9M. The 52-week trading range was $6.47 to $16.10. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.